Kroll Ashley V, Jiang Yao, Zhou Jiarong, Holay Maya, Fang Ronnie H, Zhang Liangfang
Department of NanoEngineering and Moores Cancer Center, University of California San Diego, La Jolla, CA, 92093, USA.
Adv Biosyst. 2019 Jan;3(1):e1800219. doi: 10.1002/adbi.201800219. Epub 2018 Nov 13.
It is currently understood that, in order for a tumor to successfully grow, it must evolve means of evading immune surveillance. In the past several decades, researchers have leveraged increases in our knowledge of tumor immunology to develop therapies capable of augmenting endogenous immunity and eliciting strong antitumor responses. In particular, the goal of anticancer vaccination is to train the immune system to properly utilize its own resources in the fight against cancer. Although attractive in principle, there are currently only limited examples of anticancer vaccines that have been successfully translated to the clinic. Recently, there has been a significant push towards the use of nanotechnology for designing vaccine candidates that exhibit enhanced potency and specificity. In this progress report, we discuss recent developments in the field of anticancer nanovaccines. By taking advantage of the flexibility offered by nanomedicine to purposefully program immune responses, this new generation of vaccines has the potential to address many of the hurdles facing traditional platforms. A specific emphasis is placed on the emergence of cell membrane-coated nanoparticles, a novel biomimetic platform that can be used to generate personalized nanovaccines that elicit strong, multi-antigenic antitumor responses.
目前人们认识到,肿瘤要成功生长,就必须进化出逃避免疫监视的手段。在过去几十年里,研究人员利用我们对肿瘤免疫学认识的增加,开发出能够增强内源性免疫并引发强烈抗肿瘤反应的疗法。特别是,抗癌疫苗的目标是训练免疫系统在对抗癌症时正确利用自身资源。虽然原则上很有吸引力,但目前成功转化到临床的抗癌疫苗例子有限。最近,人们大力推动使用纳米技术来设计具有更高效力和特异性的候选疫苗。在本进展报告中,我们讨论了抗癌纳米疫苗领域的最新进展。通过利用纳米医学提供的灵活性来有目的地调控免疫反应,新一代疫苗有潜力克服传统平台面临的许多障碍。特别强调了细胞膜包被纳米颗粒的出现,这是一种新型仿生平台,可用于生成能引发强烈多抗原抗肿瘤反应的个性化纳米疫苗。